A 7-day course of glecaprevir/pibrentasvir started in the preoperative period prevented transmission of hepatitis C virus (HCV) from viremic donors to 10 HCV-negative recipients (2 heart, 1 lung, 6 kidney, 1 heart/kidney) with 100% sustained virological response at 12 weeks.
Keywords: DAA; HCV; direct-acting antiviral; donor-derived infection; glecaprevir/pibrentasvir; prophylaxis.
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.